APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neuroendocrine Tumors (NETs) Treatment

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Neuroendocrine Tumors (NETs) Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025183 pages

Choose your research edition.

Industry ResearchNeuroendocrine Tumors (NETs) Treatment Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Neuroendocrine Tumors (NETs) Treatment Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Neuroendocrine Tumors (NETs) Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neuroendocrine Tumors (NETs) Treatment Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Neuroendocrine Tumors (NETs) Treatment Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Neuroendocrine Tumors (NETs) Treatment market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Neuroendocrine Tumors (NETs) Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neuroendocrine Tumors (NETs) Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neuroendocrine Tumors (NETs) Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Neuroendocrine Tumors (NETs) Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Neuroendocrine Tumors (NETs) Treatment include Novartis AG, Pfizer, Inc, Progenics Pharmaceuticals, IpsenPharma, Hutchison MediPharma Limited, Boehringer Ingelheim International, AVEO Oncology and Advanced Accelerator Applications, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Neuroendocrine Tumors (NETs) Treatment market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neuroendocrine Tumors (NETs) Treatment and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neuroendocrine Tumors (NETs) Treatment sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Neuroendocrine Tumors (NETs) Treatment market size, projected growth trends, production technologies, key applications, and end-use industries.

Neuroendocrine Tumors (NETs) Treatment Segment by Company

Novartis AG

Pfizer, Inc

Progenics Pharmaceuticals

IpsenPharma

Hutchison MediPharma Limited

Boehringer Ingelheim International

AVEO Oncology

Advanced Accelerator Applications

Neuroendocrine Tumors (NETs) Treatment Segment by Type

Somatostatin Analogs (SSAs)

Targeted Therapy

Other

Neuroendocrine Tumors (NETs) Treatment Segment by Application

Hospitals

Clinics

Other

Neuroendocrine Tumors (NETs) Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuroendocrine Tumors (NETs) Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neuroendocrine Tumors (NETs) Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuroendocrine Tumors (NETs) Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Neuroendocrine Tumors (NETs) Treatment market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Neuroendocrine Tumors (NETs) Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Neuroendocrine Tumors (NETs) Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Neuroendocrine Tumors (NETs) Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Neuroendocrine Tumors (NETs) Treatment Industry Trends Table 2. Neuroendocrine Tumors (NETs) Treatment Industry Drivers Table 3. Neuroendocrine Tumors (NETs) Treatment Industry Opportunities and Challenges Table 4. Neuroendocrine Tumors (NETs) Treatment Industry Restraints Table 5. Global Neuroendocrine Tumors (NETs) Treatment Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Neuroendocrine Tumors (NETs) Treatment Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Manufacturers Table 9. Global Neuroendocrine Tumors (NETs) Treatment Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Neuroendocrine Tumors (NETs) Treatment Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Neuroendocrine Tumors (NETs) Treatment Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Neuroendocrine Tumors (NETs) Treatment Manufacturers, Product Type & Application Table 13. Global Neuroendocrine Tumors (NETs) Treatment Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Neuroendocrine Tumors (NETs) Treatment by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Somatostatin Analogs (SSAs) Table 17. Major Manufacturers of Targeted Therapy Table 18. Major Manufacturers of Other Table 19. Global Neuroendocrine Tumors (NETs) Treatment Sales by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Neuroendocrine Tumors (NETs) Treatment Sales by Type (2021-2026) & (k units) Table 21. Global Neuroendocrine Tumors (NETs) Treatment Sales by Type (2027-2032) & (k units) Table 22. Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Type (2021-2026) Table 23. Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Type (2027-2032) Table 24. Global Neuroendocrine Tumors (NETs) Treatment Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 25. Global Neuroendocrine Tumors (NETs) Treatment Revenue by Type (2021-2026) & (k units) Table 26. Global Neuroendocrine Tumors (NETs) Treatment Revenue by Type (2027-2032) & (k units) Table 27. Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Type (2021-2026) Table 28. Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Hospitals Table 30. Major Manufacturers of Clinics Table 31. Major Manufacturers of Other Table 32. Global Neuroendocrine Tumors (NETs) Treatment Sales by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Neuroendocrine Tumors (NETs) Treatment Sales by Application (2021-2026) & (k units) Table 34. Global Neuroendocrine Tumors (NETs) Treatment Sales by Application (2027-2032) & (k units) Table 35. Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Application (2021-2026) Table 36. Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Application (2027-2032) Table 37. Global Neuroendocrine Tumors (NETs) Treatment Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 38. Global Neuroendocrine Tumors (NETs) Treatment Revenue by Application (2021-2026) & (k units) Table 39. Global Neuroendocrine Tumors (NETs) Treatment Revenue by Application (2027-2032) & (k units) Table 40. Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Application (2021-2026) Table 41. Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Application (2027-2032) Table 42. Global Neuroendocrine Tumors (NETs) Treatment Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Neuroendocrine Tumors (NETs) Treatment Sales by Region (2021-2026) & (k units) Table 44. Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Region (2021-2026) Table 45. Global Neuroendocrine Tumors (NETs) Treatment Sales Forecasted by Region (2027-2032) & (k units) Table 46. Global Neuroendocrine Tumors (NETs) Treatment Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Neuroendocrine Tumors (NETs) Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 48. North America Neuroendocrine Tumors (NETs) Treatment Sales by Country (2021-2026) & (k units) Table 49. North America Neuroendocrine Tumors (NETs) Treatment Sales by Country (2027-2032) & (k units) Table 50. Europe Neuroendocrine Tumors (NETs) Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 51. Europe Neuroendocrine Tumors (NETs) Treatment Sales by Country (2021-2026) & (k units) Table 52. Europe Neuroendocrine Tumors (NETs) Treatment Sales by Country (2027-2032) & (k units) Table 53. Asia Pacific Neuroendocrine Tumors (NETs) Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Asia Pacific Neuroendocrine Tumors (NETs) Treatment Sales by Country (2021-2026) & (k units) Table 55. Asia Pacific Neuroendocrine Tumors (NETs) Treatment Sales by Country (2027-2032) & (k units) Table 56. South America, Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 57. South America, Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Sales by Country (2021-2026) & (k units) Table 58. South America, Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Sales by Country (2027-2032) & (k units) Table 59. Global Neuroendocrine Tumors (NETs) Treatment Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Neuroendocrine Tumors (NETs) Treatment Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Neuroendocrine Tumors (NETs) Treatment Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Region (2021-2026) Table 63. Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Region (2027-2032) Table 64. Novartis AG Company Information Table 65. Novartis AG Business Overview Table 66. Novartis AG Neuroendocrine Tumors (NETs) Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Novartis AG Neuroendocrine Tumors (NETs) Treatment Product Portfolio Table 68. Novartis AG Recent Development Table 69. Pfizer, Inc Company Information Table 70. Pfizer, Inc Business Overview Table 71. Pfizer, Inc Neuroendocrine Tumors (NETs) Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Pfizer, Inc Neuroendocrine Tumors (NETs) Treatment Product Portfolio Table 73. Pfizer, Inc Recent Development Table 74. Progenics Pharmaceuticals Company Information Table 75. Progenics Pharmaceuticals Business Overview Table 76. Progenics Pharmaceuticals Neuroendocrine Tumors (NETs) Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Progenics Pharmaceuticals Neuroendocrine Tumors (NETs) Treatment Product Portfolio Table 78. Progenics Pharmaceuticals Recent Development Table 79. IpsenPharma Company Information Table 80. IpsenPharma Business Overview Table 81. IpsenPharma Neuroendocrine Tumors (NETs) Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. IpsenPharma Neuroendocrine Tumors (NETs) Treatment Product Portfolio Table 83. IpsenPharma Recent Development Table 84. Hutchison MediPharma Limited Company Information Table 85. Hutchison MediPharma Limited Business Overview Table 86. Hutchison MediPharma Limited Neuroendocrine Tumors (NETs) Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Hutchison MediPharma Limited Neuroendocrine Tumors (NETs) Treatment Product Portfolio Table 88. Hutchison MediPharma Limited Recent Development Table 89. Boehringer Ingelheim International Company Information Table 90. Boehringer Ingelheim International Business Overview Table 91. Boehringer Ingelheim International Neuroendocrine Tumors (NETs) Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Boehringer Ingelheim International Neuroendocrine Tumors (NETs) Treatment Product Portfolio Table 93. Boehringer Ingelheim International Recent Development Table 94. AVEO Oncology Company Information Table 95. AVEO Oncology Business Overview Table 96. AVEO Oncology Neuroendocrine Tumors (NETs) Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. AVEO Oncology Neuroendocrine Tumors (NETs) Treatment Product Portfolio Table 98. AVEO Oncology Recent Development Table 99. Advanced Accelerator Applications Company Information Table 100. Advanced Accelerator Applications Business Overview Table 101. Advanced Accelerator Applications Neuroendocrine Tumors (NETs) Treatment Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Advanced Accelerator Applications Neuroendocrine Tumors (NETs) Treatment Product Portfolio Table 103. Advanced Accelerator Applications Recent Development Table 104. Key Raw Materials Table 105. Raw Materials Key Suppliers Table 106. Neuroendocrine Tumors (NETs) Treatment Distributors List Table 107. Neuroendocrine Tumors (NETs) Treatment Customers List Table 108. Research Programs/Design for This Report Table 109. Authors List of This Report Table 110. Secondary Sources Table 111. Primary Sources List of Figures Figure 1. Neuroendocrine Tumors (NETs) Treatment Product Image Figure 2. Global Neuroendocrine Tumors (NETs) Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neuroendocrine Tumors (NETs) Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Neuroendocrine Tumors (NETs) Treatment Sales (2021-2032) & (k units) Figure 5. Global Neuroendocrine Tumors (NETs) Treatment Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Neuroendocrine Tumors (NETs) Treatment Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Somatostatin Analogs (SSAs) Image Figure 9. Targeted Therapy Image Figure 10. Other Image Figure 11. Global Neuroendocrine Tumors (NETs) Treatment Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Type (2021-2032) Figure 14. Global Neuroendocrine Tumors (NETs) Treatment Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Type (2021-2032) Figure 17. Hospitals Image Figure 18. Clinics Image Figure 19. Other Image Figure 20. Global Neuroendocrine Tumors (NETs) Treatment Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Application (2021-2032) Figure 23. Global Neuroendocrine Tumors (NETs) Treatment Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Application (2021-2032) Figure 26. North America Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 27. North America Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Country (2021-2032) Figure 28. U.S. Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 29. Canada Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 30. Mexico Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 31. Europe Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 32. Europe Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Country (2021-2032) Figure 33. Germany Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 34. France Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 35. U.K. Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 36. Italy Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 37. Netherlands Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 38. Asia Pacific Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 39. Asia Pacific Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Country (2021-2032) Figure 40. China Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 41. Japan Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 42. South Korea Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 43. Southeast Asia Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 44. India Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 45. Australia Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 46. South America, Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 47. South America, Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Country (2021-2032) Figure 48. Brazil Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 49. South Africa Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 50. Saudi Arabia Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 51. Turkey Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 52. Argentina Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 53. UAE Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 54. Egypt Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 55. Chile Neuroendocrine Tumors (NETs) Treatment Sales and Growth Rate (2021-2032) & (k units) Figure 56. Global Neuroendocrine Tumors (NETs) Treatment Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Neuroendocrine Tumors (NETs) Treatment Revenue (2021-2032) & (US$ Million) Figure 59. North America Neuroendocrine Tumors (NETs) Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Neuroendocrine Tumors (NETs) Treatment Revenue (2021-2032) & (US$ Million) Figure 61. Europe Neuroendocrine Tumors (NETs) Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Neuroendocrine Tumors (NETs) Treatment Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Neuroendocrine Tumors (NETs) Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Neuroendocrine Tumors (NETs) Treatment Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Neuroendocrine Tumors (NETs) Treatment Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Somatostatin Analogs (SSAs)
  • Targeted Therapy
  • Other
Applications
  • Hospitals
  • Clinics
  • Other
Companies covered
  • Novartis AG
  • Pfizer, Inc
  • Progenics Pharmaceuticals
  • IpsenPharma
  • Hutchison MediPharma Limited
  • Boehringer Ingelheim International
  • AVEO Oncology
  • Advanced Accelerator Applications

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Neuroendocrine Tumors (NETs) Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Neuroendocrine Tumors (NETs) Treatment Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Neuroendocrine Tumors (NETs) Treatment Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Neuroendocrine Tumors (NETs) Treatment Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Neuroendocrine Tumors (NETs) Treatment Market Dynamics
  1. 2.1 Neuroendocrine Tumors (NETs) Treatment Industry Trends
  2. 2.2 Neuroendocrine Tumors (NETs) Treatment Industry Drivers
  3. 2.3 Neuroendocrine Tumors (NETs) Treatment Industry Opportunities and Challenges
  4. 2.4 Neuroendocrine Tumors (NETs) Treatment Industry Restraints
3 Neuroendocrine Tumors (NETs) Treatment Market by Manufacturers
  1. 3.1 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Neuroendocrine Tumors (NETs) Treatment Sales by Manufacturers (2021-2026)
  3. 3.3 Global Neuroendocrine Tumors (NETs) Treatment Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Neuroendocrine Tumors (NETs) Treatment Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Neuroendocrine Tumors (NETs) Treatment Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Neuroendocrine Tumors (NETs) Treatment Manufacturers, Product Type & Application
  7. 3.7 Global Neuroendocrine Tumors (NETs) Treatment Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Neuroendocrine Tumors (NETs) Treatment Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Neuroendocrine Tumors (NETs) Treatment Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Neuroendocrine Tumors (NETs) Treatment Tier 1, Tier 2, and Tier 3
4 Neuroendocrine Tumors (NETs) Treatment Market by Type
  1. 4.1 Neuroendocrine Tumors (NETs) Treatment Type Introduction
  2. 4.1.1 Somatostatin Analogs (SSAs)
  3. 4.1.2 Targeted Therapy
  4. 4.1.3 Other
  5. 4.2 Global Neuroendocrine Tumors (NETs) Treatment Sales by Type
  6. 4.2.1 Global Neuroendocrine Tumors (NETs) Treatment Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Neuroendocrine Tumors (NETs) Treatment Sales by Type (2021-2032)
  8. 4.2.3 Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Type (2021-2032)
  9. 4.3 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Type
  10. 4.3.1 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Type (2021-2032)
  12. 4.3.3 Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Type (2021-2032)
5 Neuroendocrine Tumors (NETs) Treatment Market by Application
  1. 5.1 Neuroendocrine Tumors (NETs) Treatment Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Other
  5. 5.2 Global Neuroendocrine Tumors (NETs) Treatment Sales by Application
  6. 5.2.1 Global Neuroendocrine Tumors (NETs) Treatment Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Neuroendocrine Tumors (NETs) Treatment Sales by Application (2021-2032)
  8. 5.2.3 Global Neuroendocrine Tumors (NETs) Treatment Sales Market Share by Application (2021-2032)
  9. 5.3 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Application
  10. 5.3.1 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Application (2021-2032)
  12. 5.3.3 Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Application (2021-2032)
6 Global Neuroendocrine Tumors (NETs) Treatment Sales by Region
  1. 6.1 Global Neuroendocrine Tumors (NETs) Treatment Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Neuroendocrine Tumors (NETs) Treatment Sales by Region (2021-2032)
  3. 6.2.1 Global Neuroendocrine Tumors (NETs) Treatment Sales by Region (2021-2026)
  4. 6.2.2 Global Neuroendocrine Tumors (NETs) Treatment Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Neuroendocrine Tumors (NETs) Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Neuroendocrine Tumors (NETs) Treatment Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Neuroendocrine Tumors (NETs) Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Neuroendocrine Tumors (NETs) Treatment Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Neuroendocrine Tumors (NETs) Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Neuroendocrine Tumors (NETs) Treatment Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Region
  1. 7.1 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Region
  2. 7.1.1 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Region (2021-2026)
  4. 7.1.3 Global Neuroendocrine Tumors (NETs) Treatment Revenue by Region (2027-2032)
  5. 7.1.4 Global Neuroendocrine Tumors (NETs) Treatment Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Neuroendocrine Tumors (NETs) Treatment Revenue (2021-2032)
  8. 7.2.2 North America Neuroendocrine Tumors (NETs) Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Neuroendocrine Tumors (NETs) Treatment Revenue (2021-2032)
  11. 7.3.2 Europe Neuroendocrine Tumors (NETs) Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Neuroendocrine Tumors (NETs) Treatment Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Neuroendocrine Tumors (NETs) Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Neuroendocrine Tumors (NETs) Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis AG
  2. 8.1.1 Novartis AG Company Information
  3. 8.1.2 Novartis AG Business Overview
  4. 8.1.3 Novartis AG Neuroendocrine Tumors (NETs) Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis AG Neuroendocrine Tumors (NETs) Treatment Product Portfolio
  6. 8.1.5 Novartis AG Recent Developments
  7. 8.2 Pfizer, Inc
  8. 8.2.1 Pfizer, Inc Company Information
  9. 8.2.2 Pfizer, Inc Business Overview
  10. 8.2.3 Pfizer, Inc Neuroendocrine Tumors (NETs) Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer, Inc Neuroendocrine Tumors (NETs) Treatment Product Portfolio
  12. 8.2.5 Pfizer, Inc Recent Developments
  13. 8.3 Progenics Pharmaceuticals
  14. 8.3.1 Progenics Pharmaceuticals Company Information
  15. 8.3.2 Progenics Pharmaceuticals Business Overview
  16. 8.3.3 Progenics Pharmaceuticals Neuroendocrine Tumors (NETs) Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Progenics Pharmaceuticals Neuroendocrine Tumors (NETs) Treatment Product Portfolio
  18. 8.3.5 Progenics Pharmaceuticals Recent Developments
  19. 8.4 IpsenPharma
  20. 8.4.1 IpsenPharma Company Information
  21. 8.4.2 IpsenPharma Business Overview
  22. 8.4.3 IpsenPharma Neuroendocrine Tumors (NETs) Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 IpsenPharma Neuroendocrine Tumors (NETs) Treatment Product Portfolio
  24. 8.4.5 IpsenPharma Recent Developments
  25. 8.5 Hutchison MediPharma Limited
  26. 8.5.1 Hutchison MediPharma Limited Company Information
  27. 8.5.2 Hutchison MediPharma Limited Business Overview
  28. 8.5.3 Hutchison MediPharma Limited Neuroendocrine Tumors (NETs) Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Hutchison MediPharma Limited Neuroendocrine Tumors (NETs) Treatment Product Portfolio
  30. 8.5.5 Hutchison MediPharma Limited Recent Developments
  31. 8.6 Boehringer Ingelheim International
  32. 8.6.1 Boehringer Ingelheim International Company Information
  33. 8.6.2 Boehringer Ingelheim International Business Overview
  34. 8.6.3 Boehringer Ingelheim International Neuroendocrine Tumors (NETs) Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Boehringer Ingelheim International Neuroendocrine Tumors (NETs) Treatment Product Portfolio
  36. 8.6.5 Boehringer Ingelheim International Recent Developments
  37. 8.7 AVEO Oncology
  38. 8.7.1 AVEO Oncology Company Information
  39. 8.7.2 AVEO Oncology Business Overview
  40. 8.7.3 AVEO Oncology Neuroendocrine Tumors (NETs) Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 AVEO Oncology Neuroendocrine Tumors (NETs) Treatment Product Portfolio
  42. 8.7.5 AVEO Oncology Recent Developments
  43. 8.8 Advanced Accelerator Applications
  44. 8.8.1 Advanced Accelerator Applications Company Information
  45. 8.8.2 Advanced Accelerator Applications Business Overview
  46. 8.8.3 Advanced Accelerator Applications Neuroendocrine Tumors (NETs) Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Advanced Accelerator Applications Neuroendocrine Tumors (NETs) Treatment Product Portfolio
  48. 8.8.5 Advanced Accelerator Applications Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Neuroendocrine Tumors (NETs) Treatment Value Chain Analysis
  2. 9.1.1 Neuroendocrine Tumors (NETs) Treatment Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Neuroendocrine Tumors (NETs) Treatment Production Mode & Process
  6. 9.2 Neuroendocrine Tumors (NETs) Treatment Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Neuroendocrine Tumors (NETs) Treatment Distributors
  9. 9.2.3 Neuroendocrine Tumors (NETs) Treatment Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst